Pharmesis International Competitors and Similar CompaniesClear all

Pharmesis International's competitors and similar companies include Laboratorios Farmaceuticos ROVI, Ind-Swift, MINAPHARM Pharmaceuticals and Arkopharma.

	Pharmesis International Pharmesis International is a company that produces and, sells medicine formulated products for the treatment of illnesses relating to the liver and gall bladder.	Laboratorios Farmaceuticos ROVI Laboratorios Farmaceuticos ROVI produces and sells pharmaceutical products.	Ind-Swift Ind-Swift is a pharmaceutical manufacturing and marketing company.	MINAPHARM Pharmaceuticals MINAPHARM operates as a pharmaceutical company.	Arkopharma Arkopharma is a pharmaceutical company that specializes in the area of phytotherapy, natural medicine, and nutritional supplements.
Founding Date	Founding Date 1996	Founding Date 1946	Founding Date 1986	Founding Date 1958	Founding Date 1980
Type	Type Public	Type Public	Type Public	Type Private	Type Private
Tags	Tags Healthcare drug development pharma supplements	Tags Healthcare drug development pharma supplements	Tags Healthcare drug development pharma supplements	Tags Healthcare drug development pharma supplements	Tags Healthcare drug development pharma supplements
Locations	Locations HQ	Locations Pozuelo de Alarcón, ES HQ Seyssins, FR Holzkirchen, DE Milano, IT Warszawa, PL Parede, PT Barcelona, ES see more	Locations Chandigarh, IN HQ Mumbai, IN Navi Mumbai, IN	Locations EG HQ	Locations Bevera, IT HQ
Employees	Employees N/A	Employees 2,197	Employees 1,054	Employees 953	Employees 835
Financial
Revenue (est.)	Revenue (est.) ¥43.8m (FY, 2025)	Revenue (est.) N/A	Revenue (est.) ₹5.2b (FY, 2025)	Revenue (est.) N/A	Revenue (est.) N/A
Cost of goods	Cost of goods ¥24.9m (FY, 2025)	Cost of goods N/A	Cost of goods ₹2.6b (FY, 2025)	Cost of goods N/A	Cost of goods N/A
Gross profit	Gross profit ¥20.8m (FY, 2025)	Gross profit N/A	Gross profit ₹3b (FY, 2025)	Gross profit N/A	Gross profit N/A
Net income	Net income (¥4.3m) (FY, 2025)	Net income N/A	Net income ₹2.8b (FY, 2025)	Net income N/A	Net income N/A